Use of faricimab for refractory diabetic macular edema in real-world clinical practice: When anatomical success meets functional limits

Zheyao Gu, Ting Xi, Xiangying Luo · 2026

Read Use of faricimab for refractory diabetic macular edema in real-world clinical practice: When anatomical success meets functional limits by Zheyao Gu, Ting Xi, Xiangying Luo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358993.txt.

Description

Zheyao Gu, Ting Xi, and Xiangying Luo report real world results for an eye injection drug in stubborn diabetic swelling, in PLOS ONE in 2026. Diabetic macular edema blurs central vision when fluid leaks into the retina. Faricimab is a newer antibody treatment. The team reviewed one hundred ten treated eyes over a year of loading and flexible dosing. Some eyes were new to therapy. Others had already failed different drugs.

Retinal thickness fell significantly in both groups, and scans showed fewer cysts, less fluid, and fewer warning spots. Vision, though, only improved clearly in eyes new to treatment; eyes that had resisted earlier drugs gained little sight despite looking better on scans. Those hard cases also carried more structural damage at the start. The gap between anatomy and eyesight, the authors note, should temper promises to long standing patients.

Catalog record

CREATORZheyao Gu, Ting Xi, Xiangying Luo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37046
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0358993

Browse the full library · About the Tower of Babel